IMO,Its been pointed out that NW, during 2016 was unsatisfied with NWBO and their handling of the investigation. As a result of that, he engaged in what some believe to be an attempt at a hostile TO of NWBO throughout the course of the year. However, his position has remained relatively unchanged, if not increased through his investment holdings. His message conveys his frustrations as a reflection of how NWBO was handling his investigatory request in 2016, but I believe he and the board have come to terms with their strategic plan going forward (late in 2016). He is guardedly optimistic for 2017 and for what many shareholders believe to be just reason. Fortunately, his belief in the DC approach, potential for AA, and upcoming partnership trials with BMY and Merck has seen him through. I genuinely believe that we will get some news over the next two days. It may not be the big news everyone speculates, but I firmly believe there will be an update - perhaps regarding Coffer Black's findings. If not a PR tomorrow morning, I expect an update from LP's talk at the conference in the late afternoon. NWBO's board has learned form others making "mistakes" in a highly manipulated biotech sector, and while I can't claim to understand every small decision they make, I still think the plan is valid and is in the overall best interest of the patients and the majority of the shareholders. GLTA, and I hope to be celebrating good news with you all by end of week.